Investors who bought Summit Therapeutics on the strength of its PFS data now have a harder number to work with: updated overall survival results from the 438-patient HARMONi Phase III trial were presented September 15 at the IASLC World Conference on Lung Cancer, and the company filed an 8-K the same day to flag the release. The trial tests ivonescimab plus chemotherapy against placebo plus chemotherapy in patients with locally advanced or metastatic, EGFR-mutated nonsquamous NSCLC who progressed on a third-generation EGFR TKI, the population where standard options run thin after osimertinib failure.
Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF simultaneously, a dual mechanism that distinguishes it from checkpoint monotherapies in this setting. HARMONi carries co-primary endpoints of progression-free survival and overall survival, meaning the OS readout presented at WCLC is not exploratory: it counts. Whether the updated OS curves hold the same directional consistency seen in PFS will shape how seriously regulators treat the BLA Summit will eventually need to file, and the company already holds FDA Fast Track designation for this exact indication.
The practical question is magnitude. PFS improvements in post-EGFR-TKI NSCLC have a track record of not translating cleanly into OS benefit, partly because subsequent therapies muddy the survival curves. A durable OS signal from a 438-patient randomized trial in a molecularly defined population is harder to dismiss than a PFS advantage alone, but the conference presentation will determine whether the data are mature enough to be persuasive or simply trending in the right direction. The 8-K text the SEC received is truncated, so full hazard ratios and confidence intervals are not yet in hand from this filing.
Summit’s next concrete marker is the full dataset from WCLC, which will show whether the OS benefit crosses a pre-specified threshold or remains an encouraging trend requiring longer follow-up before a regulatory submission can anchor on it.
Source link: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/smmt-20260915.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
